It was billed as a transformative deal that would drive a transformative company. And it happened just two years ago. Founded in 2003, Sublimity Therapeutics, a Dublin drug development company, had already raised around €38 million to finance the advancement of a treatment for ulcerative colitis. Then in May 2018, the company announced that it was raising a further €55 million from a host of heavy-hitting investors. It was, according to Anthony J Giovinazzo, an industry veteran installed as executive chairman at the time of the 2018 deal, an “important milestone” for the company, which was previously known as Sigmoid…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .